Academic literature on the topic 'Wasting Syndrome, diet therapy'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Wasting Syndrome, diet therapy.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Wasting Syndrome, diet therapy"
1
Szeredi, Levente, and Csaba Szentirmai. "Gastric zygomycosis in a pig affected with postweaning multisystemic wasting syndrome — Case report." Acta Veterinaria Hungarica 56, no. 2 (June 1, 2008): 207–13. http://dx.doi.org/10.1556/avet.56.2008.2.8.
Full textAbstract:
A postweaning pig died in spite of antibiotic therapy showing wasting in a small herd. Postweaning multisystemic wasting syndrome (PMWS) was diagnosed on the basis of gross pathological and histological lesions and the presence of moderate amounts of porcine circovirus 2 (PCV2) antigen in tissue samples. Mycotic gastritis caused by Zygomycetes spp. was found on round areas with a diameter of 1 to 3 cm in the glandular mucosa of the stomach. Moderate amount of PCV2 viral antigen was detected almost evently in the stomach and mostly in the macrophages. In addition, acute uraemia, revealed by an ammonia-like stink of the gastric mucosa and the presence of acute erosions on the glandular mucosa of the stomach, was observed as a consequence of PCV2-induced interstitial nephritis. Only PCV2 infection could be identified as a cause of secondary mycotic gastritis. The results further support the immunosuppressive ability of PCV2 infection in PMWS-affected pigs.
2
Farrukh, Hina, Amina Mehrab, and Abeera Khan. "Adrenal Insufficiency Presenting as Hypoglycemia & Hyponatremia in a Patient With Liver Cirrhosis; Hepatoadrenal Syndrome." Journal of the Endocrine Society 5, Supplement_1 (May 1, 2021): A111. http://dx.doi.org/10.1210/jendso/bvab048.223.
Full textAbstract:
Abstract Hepatoadrenal syndrome is described as a progressive impairment in the adrenocortical reserve in advanced liver disease resulting in relative adrenal insufficiency (AI). This can present as critical hypoglycemia and hyponatremia as in the case described. 54 year old male with past medical history of hypothyroidism, pericardial effusion, liver cirrhosis and prior alcohol use disorder presented to the hospital with altered mental status. He felt lethargic and complained of recurrent diarrhea for a month. His blood sugar was 30 mg/dl (n=70–140 mg/dl) for which he received dextrose and his mentation improved. He was hypothermic with stable vitals otherwise. There was no skin hyperpigmentation. Labs demonstrated sodium of 123 mmol/L (n=136–145 mmol/L) and pancytopenia. TSH, ammonia, renal and hepatic functions were within normal limits except mildly elevated AST and total bilirubin. Total protein, albumin, HDL, Insulin and cortisol levels were low. Hepatitis panel was negative. CT Chest, abdomen and pelvis revealed massive abdominopelvic ascites, hepatic cirrhosis and splenomegaly. Adrenal glands appeared normal. Urine studies were consistent with salt-wasting nephropathy. Patient was started on intravenous fluids as well as dexamethasone. Diagnostic and therapeutic paracentesis was performed. Cosyntropin stimulation test revealed a baseline AM cortisol of 2.0 ug/dl (n=4.3–22.4 ug/dl), 30 min value of 4.0 ug/dl and 60 min value of 5.8 ug/dl (n=18-22ug/dl). Delta cortisol level was also low. Treatment with hydrocortisone was initiated until ACTH levels became available. To rule out sarcoidosis, ACE levels were obtained, which were normal. Dihydroxy 1,25 Vitamin D levels were low. ACTH returned as 21.7 pg/ml (n=7.2–63.3 pg/ml). 21 hydroxylase antibody was negative. MRI brain with IV contrast demonstrated no pituitary mass or abnormality. Blood cultures, body fluid cultures, AMA and ASMA were negative. Anti- tTG and Anti Gliadin antibodies were positive confirming celiac disease. Patient was started on gluten free diet which resolved his diarrhea. He responded well to steroids however, he remained intermittently confused which was thought to be related to hypoglycemic brain injury. Patient was converted to hydrocortisone PO 20 mg in AM and 10 mg in PM and advised to follow up outpatient with endocrinologist and gastroenterologist. Hepatoadrenal syndrome is an important differential to consider in patients with liver disease presenting with hypoglycemia and hyponatremia. It is a potentially life-threatening condition requiring immediate treatment and appropriate work up. The condition improves with corticosteroid replacement therapy. Reference: Anastasiadis SN, Giouleme OI, Germanidis GS, Vasiliadis TG. Relative adrenal insufficiency in cirrhotic patients. Clin Med Insights Gastroenterol. 2015;8:13–17. Published 2015 Mar 2. doi:10.4137/CGast.S18127
3
Ogoina, Dimie, Reginald O. Obiako, and Haruna M. Muktar. "HIV Wasting Syndrome in a Nigerian Failing Antiretroviral Therapy: A Case Report and Review of the Literature." Case Reports in Medicine 2010 (2010): 1–5. http://dx.doi.org/10.1155/2010/192060.
Full textAbstract:
The HIV wasting syndrome represented the face of HIV/AIDS before the advent of highly active antiretroviral therapy (HAART). Although the incidence of wasting has declined since the introduction of HAART, weight loss remains common in patients receiving HAART, especially in the setting of a failing HAART regimen. As we are not aware of any previous reports from Nigeria, we report a case of the classical wasting syndrome in a Nigerian female who had both virological and immunological HAART failure due to poor adherence. The influence of a failing HAART regimen, socioeconomic status, and other clinical variables in the wasting syndrome are discussed.
4
Bakulin, I. G., E. B. Avalueva, L. S. Оrеshkо, S. I. Sitkin, M. A. Shevyakov, M. U. Serkova, and E. A. Semenova. "Diet therapy for irritable bowel syndrome." Terapevticheskii arkhiv 92, no. 8 (September 3, 2020): 118–27. http://dx.doi.org/10.26442/00403660.2020.08.000759.
Full textAbstract:
The review provides present information on the pathogenesis of irritable bowel syndrome (IBS), the relationship of endogenous and exogenous factors with the development of IBS-symptoms, questions of diet therapy are discussed, diets traditionally prescribed in IBS treatment and diets, such as FODMAP and gluten-free diet, which are the most promising and have a positive effect on the symptoms of IBS.
5
Balog, Denise L., Marcia E. Epstein, and Maria I. Amodio-Groton. "HIV Wasting Syndrome: Treatment Update." Annals of Pharmacotherapy 32, no. 4 (April 1998): 446–58. http://dx.doi.org/10.1345/aph.17072.
Full textAbstract:
OBJECTIVE: To review the pathophysiology and treatment of HIV wasting syndrome. DATA SOURCES AND STUDY SELECTION: MEDLINE searches (January 1987–September 1997) of the English-language medical literature were conducted. Bibliographies were also selected during a manual review. DATA SYNTHESIS: HIV-related weight loss, often referred to as HIV wasting syndrome, is a common manifestation of advanced HIV infection. Wasting in HIV involves the preferential loss of lean body mass with a paradoxical preservation of body fat. The etiology of wasting appears to be the result of many factors, which may include decreased caloric intake, malabsorption, alterations in energy expenditure and metabolism, cytokine effects, and endocrine dysfunction. Pharmacologic treatment options include appetite stimulants (e.g., dronabinol, megestrol acetate), cytokine inhibitors (e.g., thalidomide, cyproheptadine, ketotifen, pentoxifylline, fish oil, N-acetylcysteine), and anabolic agents (e.g., testosterone, nandrolone, oxandrolone, recombinant human growth hormone). CONCLUSIONS: Wasting associated with HIV has a high morbidity and mortality rate if not adequately managed. Therapeutic strategies include appetite stimulants, cytokine inhibitors, and growth-promoting agents. Selection of the appropriate agent(s) depends on the underlying cause for weight loss, adverse effects, and cost of therapy. OBJETIVO: Revisar la patofisiología y tratamiento del síndrome de desgaste causado por el VIH. FUENTES DE DATOS: Se llevó a cabo una búsqueda de la literatura médica en el idioma inglés utilizando la base de datos del MEDLINE. SÍNTESIS: La pérdida de peso asociado al VIH, también conocido como el síndrome de desgaste, es una manifestación común de la infección avanzada causada por el virus. El desgaste envuelve principalmente la pérdida de masa magra, y paradójicamente la preservación de grasa corporal. La etiología del síndrome de desgaste aparenta ser el resultado de varios factores que pueden incluir la disminución de ingesta calórica, malabsorción, alteración en la utilización de energía, alteración del metabolismo, efectos de las citoquinas, y disfunción endocrina. Las opciones para el tratamiento farmacológico incluyen estimuladores del apetito (dronabinol y acetato de megestrol), inhibidores de citoquinas (talidomida, ciproheptadina, ketotifen, pentoxyfilina, accite de pescado, y N-acetil cisteína), y agentes anabólicos (testosterona, nandrolona, oxandrolona, y la hormona de crecimiento). CONCLUSIONES: La etiología del desgaste asociado a la infección con el VIH es multifactorial. La condición conlieva una alta morbilidad y mortalidad si no es manejada adecuadamente. Las estrategías terapéuticas incluyen la estimulación de apetito, inhibidores de citoquinas y agentes que promueven el crecimiento. La selección de los agentes apropiados dependerá de la causa de la pérdida de peso, los efectos adversos, y el costo de la terapia. Aunque se necesita estudiar la condición más a fondo, la terapia combinada puede ser que resulte ser la modalidad de mayor beneficio para el paciente con el síndrome de desgaste por el VIH. OBJECTIF: Réviser la pathophysiologie et le traitement du syndrome d'émaciation associé au VIH. REVUE DE LITTÉRATURE ET SÉLECTION DES ÉTUDES: Une recherche de la documentation médicale de langue anglaise a été effectuée à l'aide de MEDLINE. Des bibliographies ont aussi été choisies grâce à une révision manuelle. RÉSUMÉ: La perte de poids associée au VIH, souvent appelée le syndrome d'émaciation, est une manifestation fréquente d'une infection avancée au VIH. l'émaciation chez les patients infectés par le VIH entraîne une perte préférentielle du tissu maigre et une conservation du tissu adipeux. l'étiologie du syndrome semble être le résultat de plusieurs facteurs dont l'ingestion calorique, la malabsorption, les modifications au niveau de la dépense énergétique et du métabolisme, les effets des cytokines, et les anormalités endocriniennes. Les options du traitement pharmacologique incluent les stimulants de l'appétit (le dronabinol et l'acétate de mégestrol), les inhibiteurs des cytokines (le thalidomide, la cyproheptadine, le kétotifène, la pentoxifylline, l'huile de poisson, et le N-acétylcystéine), et des agents anabolisants (la testostérone, le nandrolone, l'oxandrolone, et l'hormone de croissance humaine recombinée). CONCLUSIONS: Le syndrome d'émaciation associé au VIH a un taux de morbidité et de mortalité élevé s'il n'est pas adéquatement traité. Les stratégies thérapeutiques incluent les stimulants de l'appétit, les inhibiteurs des cytokines, et les agents stimulant la croissance. La sélection du ou des agents appropriés dépendra de la cause sous-jacente de la perte de poids, des effets indésirables, et du coût de la thérapie.
6
Kong, Anthony, and Polly Edmonds. "Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis." Lancet Infectious Diseases 2, no. 11 (November 2002): 692–99. http://dx.doi.org/10.1016/s1473-3099(02)00441-3.
Full text
7
Sheptulin, A. A., S. S. Kardasheva, A. A. Kurbatova, and V. T. Ivashkin. "Diet therapy for irritable bowel syndrome: controversial and unresolved issues." Voprosy detskoj dietologii 18, no. 4 (2020): 29–35. http://dx.doi.org/10.20953/1727-5784-2020-4-29-35.
Full textAbstract:
The review considers modern approaches to diet therapy of irritable bowel syndrome (IBS). Along with general recommendations on eating regimens most commonly used nowadays in treatment of IBS, attention is paid to the lactose-free diet, gluten-free diet and the low-FODMAP diet. As is pointed out, there are contradictions in the published data concerning the effectiveness of these diets. The authors come to the conclusion that many important aspects of diet therapy for IBS remain insufficiently studied and further research is needed. Key words: irritable bowel syndrome, lactose-free diet, gluten-free diet, low-FODMAP diet
8
Zafonte, Ross D., and Nancy R. Mann. "Cerebral salt wasting syndrome in brain injury patients: A potential cause of hyponatremia." Archives of Physical Medicine and Rehabilitation 78, no. 5 (May 1997): 540–42. http://dx.doi.org/10.1016/s0003-9993(97)90173-8.
Full text
9
Amankwah, Samuel, and Henry G. Fein. "Hyperaldosteronism in a Patient With Gastrointestinal Potassium Wasting." Journal of the Endocrine Society 5, Supplement_1 (May 1, 2021): A134. http://dx.doi.org/10.1210/jendso/bvab048.270.
Full textAbstract:
Abstract Background: Medical conditions causing hypokalemia can be masked by a diet very rich in potassium. The following case presents a patient who developed new onset symptoms of hypokalemia after immigrating to the United States. Clinical Case: A 35 year old man, native of Mali, had a history of intermittent muscle spasms and serum potassium of 3.0 mmol/L first recognized elsewhere in 2019. He was not on any home medications. He was admitted with postprandial generalized abdominal pain, diarrhea, and bright blood in his stools. Serum potassium was 2.7 (nl 3.5–5.1mmol/L). He required at least 120 mEq of intravenous and oral potassium chloride per day while hospitalized to achieve and maintain serum potassium in the normal range. Colonoscopy found segmental colitis and it was thought that his hypokalemia was due to gastrointestinal losses. However, studies demonstrated urinary potassium wasting. A 1.9 cm nodular mass of the left adrenal gland was found on CT of the abdomen, and the differential diagnosis was expanded to include hypokalemia secondary to primary hyperaldosteronism or renal tubulopathies such as Bartter and Gitleman syndromes. The patient was normotensive and had biochemical findings that were consistent with Bartter syndrome including metabolic alkalosis, hypercalciuria, elevated urine sodium and chloride, and normal serum magnesium levels. However, he had low plasma rennin activity with an elevated serum aldosterone on three tests over two months (the last test was more than one month after normalization of bowel function). On all of these, the aldosterone to renin ratio was greater than 20 ng/mL/hour. The persistent suppression of plasma rennin with elevated aldosterone in the setting of left adrenal mass narrowed the differential diagnosis to primary hyperaldosteronism, as elevated rennin would be expected in Bartter syndrome. Since discharge, he has received 80 meq of daily oral potassium in divided doses, which has kept serum potassium at or below the lower limit of normal. Further management will consist of either pharmacologic or surgical treatment with or without adrenal venous sampling. Conclusion: The patient had hypokalemia for which an endocrine etiology could have been easily overlooked and attributed to gastrointestinal losses. This case demonstrates the very close clinical similarities between primary hyperaldosteronism and renal tubulopathies. However, there are biochemical patterns that can be relied on to help differentiate amongst these disorders. This patient with primary hyperaldosteronism may not have been hypokalemic in his native country due to consuming a diet rich in potassium.
10
Bekker, Yvonne A. C., Danielle A. Lambrechts, Judith S. Verhoeven, Jessy van Boxtel, Caroline Troost, Erik-Jan Kamsteeg, Michèl A. Willemsen, and Hilde M. H. Braakman. "Failure of ketogenic diet therapy in GLUT1 deficiency syndrome." European Journal of Paediatric Neurology 23, no. 3 (May 2019): 404–9. http://dx.doi.org/10.1016/j.ejpn.2019.02.012.
Full textDissertations / Theses on the topic "Wasting Syndrome, diet therapy"
1
Caspero, Alexandra M. "Usual dietary intake among chronic fatigue syndrome patients." Scholarly Commons, 2009. https://scholarlycommons.pacific.edu/uop_etds/729.
Full textAbstract:
The relationship between dietary intake and the pathology of CFS has been an area of intense speculation without strong research support. There may be important links between diet and symptoms such that dietary interventions may be efficacious as adjunct therapy. This study was designed to assess any dietary abnormalities among Chronic Fatigue Syndrome patients. The purpose of this study is to make a controlled assessment of usual dietary intake so that dietary recommendations for CFS patients can be made. A Diet History Questionnaire, provided by the National Institute of Health, was used to analyze usual dietary intake among CFS patients. Women, ages I 8 and older, diagnosed by a physician with CFS, and were asked to complete the online survey. To complete the questionnaire, participants were provided with a user name and password and asked to answer a number of questions about their dietary habit. Twenty (n=20) women with CFS completed the questionnaire. The results were compiled and analyzed using Diet-Calc software and compared with nonnative data. Several nutrients were found to be deficient in more than 75% of the CFS patients.
2
Kudlas, Jane Michele. "Low-fat diet vs. education support in the treatment of late luteal phase dysphoric disorder." Diss., Virginia Tech, 1992. http://hdl.handle.net/10919/39719.
Full textAbstract:
A treatment outcome study was conducted comparing a low-fat diet intervention with an education-support group and a waiting-list control group in the treatment of premenstrual tension syndrome (PMS) or Late Luteal Phase Dysphoric Disorder (LLPDD). Subjects met provisional diagnostic criteria for LLPDD and symptoms were monitored prospectively. A low-fat diet was hypothesized too be an effective intervention for reducing the severity of both physical and emotional symptoms in women suffering from LLPDD. This was based on the theory relating raised estrogen levels to premenstrual distress, and research suggesting low-fat diets reduce estrogen levels.
The hypothesis that a low-fat diet would decrease premenstrual suffering was not supported by the results of this study. However, there appeared to be an advantage to participating in a group which provided support and information on LLPDD compared to receiving no treatment. Implications for future research, treatment recommendations, and methodological issues are discussed.Ph. D.
3
Rudrich, Horst R. "The reduction of the diabetic syndrome in the C57Bl/KsJ (db/db) diabetic mouse by diet-restriction and exercise." CSUSB ScholarWorks, 1985. https://scholarworks.lib.csusb.edu/etd-project/425.
Full text
4
Brenninger, Vanessa. "Establishing evidence for practice in medical nutrition therapy a case study of the impact of a high amylose resistant starch diet on clinical indicators of the insulin resistant syndrome /." Access electronically, 2005. http://www.library.uow.edu.au/adt-NWU/public/adt-NWU20060712.103548/index.html.
Full text
5
Shultz, Jennifer M. "Effects of sex steroids and diet on adipose distribution and cardiovascular disease risk factors /." Thesis, Connect to this title online; UW restricted, 2002. http://hdl.handle.net/1773/6592.
Full text
6
Weidemann, Annchen. "The role of fructose restriction in addition to dietary modifications for weight loss and lifestyle improvement, on fertility outcome and other markers of metabolic syndrome (MS), in obese women with polycystic ovarian syndrome (PCOS)." Thesis, Stellenbosch : Stellenbosch University, 2012. http://hdl.handle.net/10019.1/71878.
Full textAbstract:
Thesis (MNutr)--Stellenbosch University, 2012.ENGLISH ABSTRACT: The role of fructose restriction in addition to dietary modifications for weight loss and lifestyle improvement, on fertility outcome and other markers of metabolic syndrome, in obese women with polycystic ovarian syndrome (PCOS) Introduction: At the time at which the current study was undertaken no data, as yet, existed on whether restriction of fructose, while treating obese patients with PCOS for weight loss, improves the clinical symptoms and metabolic/anthropometric profile so as to promote fertility. Objectives: To evaluate the baseline intake of fructose, as well as the effect of restricting fructose intake from fruit and soft beverages to less than 20 g daily, as well as to provide guidelines for weight loss on anthropometric measurements, for improving subjective clinical symptoms, and for promoting fertility outcome in obese patients with PCOS, who seek to become fertile. Methods: The study was conducted in the Tygerberg Hospital Infertility Clinic, as an experimental cohort. Patients with a body mass index (BMI) higher than 27, seeking fertility after diagnosis with PCOS, were referred for dietary consultation, and followed up 3 monthly over 1 year. At each visit anthropometric measurements and a detailed dietary history were taken and a questionnaire for clinical symptoms was completed. Results: Baselinely, 86 patients were included in the study. Averages for weight and BMI were 99.8 ± 24.3 kg and 39.2 ± 8.7kg/m2, respectively. Average baseline daily fructose intake was 167 ± 116.8g. At baseline, significant relationships were shown between fructose intake and burning feet (ρ=0.02) and frequent waking (ρ=0.02), with a trend towards nightly eating (ρ=0.07). The dropout rate after visit 1 was 50%, with a further dropout of 41% after visit 2. After 3 visits (n=18), fructose intake significantly reduced (ρ=0.018), with the significant relationships with clinical symptoms having disappeared by visit 2. After 3 visits (n=18), both weight and BMI decreased significantly (ρ=0.017) and (ρ=0.019), respectively. Fructose was tested as a covariate to BMI, with high significance (ρ=0.006) in said population group. Conclusion: Dietary intervention to reduce fructose intake proved significant for weight loss and BMI after 3 visits. Reduced fructose intake was associated with reduced clinical symptoms. With fructose being a significant covariate to BMI, it can be concluded that fructose overconsumption could possibly contribute to both clinical symptoms and elevated BMI in said study population.
AFRIKAANSE OPSOMMING: Die rol wat die beperking van fruktose speel bykomend tot dieetaanpassings en lewenstylverbetering vir gewigsverlies by oorgewig vroue met polisistiese ovariële sindroom (PCOS) in die uitkoms van fertiliteit en ander merkers van metaboliese sindroom. Inleiding: Met die aanvang van hierdie studie was daar is geen data beskikbaar oor die invloed van die beperking van fruktose in die dieet van oorgewig pasiënte met PCOS wat vir gewigsverlies behandel word nie. Dit was ook nie bekend of laasgenoemde pasiënte se kliniese simptome en metaboliese/antropometriese profiel sou verbeter met die beperking van fruktose sodat fertiliteit by hierdie pasiënte terselfdertyd ook bevorder word nie. Doelwitte: Die evaluering van die aanvanklike inname van fruktose, sowel as die beperking van fruktose afkomstig van eetbare vrugte en versoete drankies en sap tot ’n inname van minder as 20 g daagliks, tesame met riglyne vir gewigsverlies. Die uitkoms hiervan is bepaal deur antropometriese metings, die verbetering in subjektiewe kliniese simptome en die fertiliteituitkoms by oorgewig pasiënte wat hulp met fertiliteit verlang. Metodes: Die studie het as ’n eksperimentele kohort by die Infertiliteitskliniek by Tygerberg Hospitaal plaasgevind. Pasiënte wat na diagnose met PCOS fertiliteitsbehandeling verlang het en ’n BMI hoër as 27 gehad het , is vir dieetbehandeling verwys en driemaandeliks oor ’n tydperk van een jaar opgevolg. Tydens elke besoek is antropometriese metings en ’n omvattende dieetgeskiedenis geneem en ’n vraelys oor kliniese simptome ingevul. Resultate: Aanvanklik is 86 pasiënte by die studie ingesluit. Gemiddeldes vir gewig en BMI was 99.8 ± 24.3 kg en 39.2 ± 8.7 kg/m2 respektiewelik. Gemiddelde aanvanklike daaglikse inname van fruktose was 167 ± 116.8 g. Oorspronklik het betekenisvolle verhoudings tussen fruktose en die volgende bestaan: brandvoete (ρ=0.02) en veelvuldige episodes van nagtelike wakkerheid (ρ=0.02), met ’n neiging na nagtelike etery (ρ=0.07). Die uitvalsyfer na een besoek was 50% met ’n verdere uitvalsyfer van 41% na die tweede besoek. Na drie besoeke (n=18) het sowel die gewig as die BMI betekenisvolle afname getoon (ρ= 0.017) en (ρ=0.019), respektiewelik. Fruktose is as ’n belangrike kovariant vir BMI (ρ= 0.006) vir hierdie populasiegroep geïdentifiseer. Gevolgtrekking: Dieetintervensie vir die vermindering van die inname van fruktose was beduidend vir gewigsverlies en afname in BMI na drie besoeke. Verminderde fruktose-inname het gelei tot die vermindering van kliniese simptome. Met fruktose as beduidende kovariant vir BMI kan die gevolgtrekking gemaak word dat die oor-inname van fruktose by hierdie studiepopulasie waarskynlik tot sowel kliniese simptome as BMI bygedra het.
7
Reid, Carol. "A randomised clinical trial to evaluate the effect of diet on quality of life of people living with HIV and lipodystrophy." Thesis, Queensland University of Technology, 2003. https://eprints.qut.edu.au/36787/2/36787_Digitised%20Thesis.pdf.
Full text
8
Moran, Lisa Jane. "Dietary management of Polycystic ovary syndrome." 2007. http://hdl.handle.net/2440/41347.
Full textAbstract:
Background Polycystic ovary syndrome (PCOS) is a common endocrine condition in women associated with obesity, reproductive and metabolic abnormalities. It improves with weight loss, however currently no specific dietary recommendations exist and there may be abnormalities in appetite regulation in PCOS that contribute to difficulty in weight management. Aims To assess the effect of 1) short and long-term weight loss and weight maintenance strategies on weight loss, reproductive and metabolic parameters in overweight women with PCOS and to 2) assess the relative effect of weight loss on cardiovascular risk factors and 3) postprandial appetite, appetite hormones (ghrelin, CCK, PYY) and food intake in overweight women with and without PCOS. Results Overweight women with PCOS followed an 8-week weight loss (2 meal replacements/day, 4904.4±127 kJ, n=32) followed by a 6 month carbohydrate (<120 g/day) or fat restricted (<50 g/day) weight maintenance regime (n=23). Reductions in weight (5.6±2.4 kg) and improvements in body composition, insulin, reproductive hormones and menstrual cyclicity occurred and were sustained equivalently for both diet groups. We then assessed the effect of weight loss (4.2±0.7 kg over 8 weeks as described above) in overweight women with (n=15) and without (n=17) PCOS on cardiovascular risk factors. All subjects had similar improvements in body composition, triglycerides, reproductive hormones and fasting and post-prandial insulin. C-reactive protein decreased with weight loss for non-PCOS women (-1.2±0.5 mg/L, P=0.025) but not for PCOS women. We finally assessed appetite regulation in PCOS. Women with (n=20) and without (n=12) PCOS followed a standard protein (55% carbohydrate, 15% protein) or high protein diet (40% carbohydrate, 30% protein) for 16 weeks (~6000 kJ/day). Non-PCOS subjects were more satiated (P=0.001) and less hungry (P=0.007) after the test meals and had a 70% higher fasting baseline ghrelin (P=0.011), a greater increase in fasting ghrelin (57.5 versus 34.0%, P=0.033), a greater post-prandial ghrelin decrease at week 16 (113.5±46.3 versus 49.3±12.2 pg/mL, P=0.05) and a greater maximal decrease in post-prandial ghrelin (-144.1±58.4 versus -28.9±14.2 pg/mL, P=0.02) following weight loss than subjects with PCOS. Lastly, women with (n=14) and without (n=14) PCOS undertook an 8-week weight loss regime (4.2±0.7 kg as described above). At week 0 and 8, women with PCOS again displayed lower ghrelin levels (P=0.01 and P=0.097 respectively) and a lesser post-prandial ghrelin decrease (P=0.048 and P=0.069 respectively) but similar post-prandial appetite, buffet consumption and fasting or post-prandial peptide YY and cholecystokinin compared to women without PCOS. Conclusion Meal replacements and moderate macronutrient restriction are effective strategies for the dietary management of PCOS. Equivalent weight losses improved cardiovascular risk factors similarly for overweight women with and without PCOS with the exception of CRP which did not decrease with weight loss for overweight women with PCOS. PCOS status is associated with altered fasting and post-prandial ghrelin levels but is not consistently associated with other impairments in post-prandial gut peptides or food intake. Further investigation is required to assess if appetite regulation is impaired in PCOS and the optimal strategies and amount of weight loss for improvement of reproductive and metabolic parameters in PCOS.http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1282329
Thesis (Ph.D.) -- University of Adelaide, School of Paediatrics and Reproductive Health, 2007
9
Moran, Lisa Jane. "Dietary management of Polycystic ovary syndrome." Thesis, 2007. http://hdl.handle.net/2440/41347.
Full textAbstract:
Background
Polycystic ovary syndrome (PCOS) is a common endocrine condition in women associated with obesity, reproductive and metabolic abnormalities. It improves with weight loss, however currently no specific dietary recommendations exist and there may be abnormalities in appetite regulation in PCOS that contribute to difficulty in weight management.
Aims
To assess the effect of 1) short and long-term weight loss and weight maintenance strategies on weight loss, reproductive and metabolic parameters in overweight women with PCOS and to 2) assess the relative effect of weight loss on cardiovascular risk factors and 3) postprandial appetite, appetite hormones (ghrelin, CCK, PYY) and food intake in overweight women with and without PCOS.
Results
Overweight women with PCOS followed an 8-week weight loss (2 meal replacements/day, 4904.4±127 kJ, n=32) followed by a 6 month carbohydrate (<120 g/day) or fat restricted (<50 g/day) weight maintenance regime (n=23). Reductions in weight (5.6±2.4 kg) and improvements in body composition, insulin, reproductive hormones and menstrual cyclicity occurred and were sustained equivalently for both diet groups. We then assessed the effect of weight loss (4.2±0.7 kg over 8 weeks as described above) in overweight women with (n=15) and without (n=17) PCOS on cardiovascular risk factors. All subjects had similar improvements in body composition, triglycerides, reproductive hormones and fasting and post-prandial insulin. C-reactive protein decreased with weight loss for non-PCOS women
(-1.2±0.5 mg/L, P=0.025) but not for PCOS women. We finally assessed appetite regulation in PCOS. Women with (n=20) and without (n=12) PCOS followed a standard protein (55% carbohydrate, 15% protein) or high protein diet (40%
carbohydrate, 30% protein) for 16 weeks (~6000 kJ/day). Non-PCOS subjects were more satiated (P=0.001) and less hungry (P=0.007) after the test meals and had a 70% higher fasting baseline ghrelin (P=0.011), a greater increase in fasting ghrelin (57.5 versus 34.0%, P=0.033), a greater post-prandial ghrelin decrease at week 16 (113.5±46.3 versus 49.3±12.2 pg/mL, P=0.05) and a greater maximal decrease in post-prandial ghrelin (-144.1±58.4 versus -28.9±14.2 pg/mL, P=0.02) following weight loss than subjects with PCOS. Lastly, women with (n=14) and without (n=14) PCOS undertook an 8-week weight loss regime (4.2±0.7 kg as described above). At week 0 and 8, women with PCOS again displayed lower ghrelin levels (P=0.01 and P=0.097 respectively) and a lesser post-prandial ghrelin decrease (P=0.048 and P=0.069 respectively) but similar post-prandial appetite, buffet consumption and fasting or post-prandial peptide YY and cholecystokinin compared to women without PCOS.
Conclusion
Meal replacements and moderate macronutrient restriction are effective strategies for the dietary management of PCOS. Equivalent weight losses improved cardiovascular risk factors
similarly for overweight women with and without PCOS with the exception of CRP which did not decrease with weight loss for overweight women with PCOS. PCOS status is associated with altered fasting and post-prandial ghrelin levels but is not consistently associated with other impairments in post-prandial gut peptides or food intake. Further investigation is required to assess if appetite regulation is impaired in PCOS and the optimal strategies and amount of weight loss for improvement of reproductive and metabolic parameters in PCOS.Thesis (Ph.D.) -- University of Adelaide, School of Paediatrics and Reproductive Health, 2007
10
Pilolla, Kari D. "Changes in body composition and metabolic syndrome risk factors : response to energy-restriction, protein intake, and high intensity interval training." Thesis, 2013. http://hdl.handle.net/1957/37898.
Full textAbstract:
Metabolic syndrome (MetS) and abdominal obesity (AbOb) increase the risk of
developing cardiovascular disease and diabetes. Energy restriction (ER), highprotein
(PRO) intake and high-intensity interval training (HIT) can independently
improve MetS and AbOb. However, ER reduces metabolically active lean body
mass (LBM) in addition to body fat (BF). Purpose: To determine the effects of a
16-wk ER diet with 2 levels of PRO (15% or 25% of energy), plus HIT, on MetS
risk factors, AbOb, and body composition in women. Methods: Sedentary,
premenopausal women (age=35±10y) with AbOb (waist circumference [WC]
≥80cm) were randomized to a 16-wk ER diet (-300kcals/d) with 15% (15PRO;
n=17) or 25% (25PRO; n=18) of energy from PRO, plus 45min/d, 3d/wk HIT and
45min/d, 2d/wk continuous moderate-intensity exercise (CME) (-200kcals/d). Diet
and physical activity (PA) were assessed using 4-d weighed food and PA
records, respectively; diet and exercise compliance were assessed monthly with
multiple-pass 24-h recalls and weekly tracking logs. Body weight (BW), WC,
DXA-assessed body composition (BF [%], BF [kg], trunk fat [kg], and LBM [kg]),
blood lipids (total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C],
low-density lipoprotein cholesterol [LDL-C], triglycerides [TG]), glycemic markers
(fasting plasma glucose [FPG], insulin, and homeostatic model assessment for
insulin resistance [HOMA-IR], beta cell function [HOMA-%β] and insulin
sensitivity [HOMA-%S]) and resting blood pressure (BP) (systolic BP [SBP];
diastolic BP [DBP]) were assessed pre/post-intervention. Repeated measures
analysis of variance and two sample t-tests were used at analyze the date.
Results are reported as means±standard deviations. Results: There were
significant time, but not group, differences in BW (-5.1±2.6kg, p=0.0141), WC (-
7.3±3.6cm, p<0.0001), TC (-18.1±17.4mg/dL, p<0.0001), LDL-C (12.2±
16.2mg/dL, p<0.0001), TG (-25.3±56.2mg/dL, p=0.0064), insulin (-2.1±4.2mg/dL,
p=0.0048), HOMA-IR (-0.2±0.5, p=0.0062), HOMA-%β (-12.1±35.2%, p=0.0497),
HOMA-%S (28.5±78.4%, p=0.0357), and SBP (-3±9mmHg, p=0.214). There
were significant group x time differences in DBP (15PRO=-5±8mmHg, 25PRO=-
2±8mmHg; p=0.0024). There were no time or group differences in FPG or HDLC.
There were significant time, but not group, effects on changes in BW (-5.1kg±
2.6, p<0.0001), BF (-3.3±1.6%, p<0.0001), and LBM (-0.6kg±1.5, p=0.0283). The
15PRO group lost more absolute whole BF (-5.2kg vs. -3.9kg, p=0.0355) and
trunk fat (-3.1kg vs. -2.2kg) vs. the 25PRO group. Conclusion: Both diets
significantly improved BW, AbOb, MetS risk factors, glycemic control, and BF
(%); LBM (kg) loss was similar in both groups. Compared to the 15PRO diet had
significantly greater absolute BF-kg and trunk fat-kg losses. Increased PRO
intake did not improve AbOb or MetS risk beyond ER and HIT/CME. The impact
of HIT/CME and the greater (-1.3kg) changes in BW in the 15PRO group may
have contributed significantly to the changes in absolute BF and trunk fat. More
research is needed to separate the impact of HIT/CME and weight loss from the
impact of PRO during ER.Graduation date: 2013
Access restricted to the OSU Community at author's request from March 28, 2013 - March 28, 2014
Books on the topic "Wasting Syndrome, diet therapy"
1
Bioactive peptides: Applications for improving nutrition and health. Boca Raton: CRC Press, 2010.
Find full text
2
Cichoke, Anthony J. AIDS and metabolic therapy (new hope). [Portland, OR: Seven C's Pub. Co., 1992.
Find full text
3
Donald, Lombard, and Horrobin David F, eds. The PMS solution: Premenstrual syndrome, the nutritional approach. Montréal: Eden Press, 1985.
Find full text
4
Nazzaro, Ann. The PMS solution: Premenstrual syndrome, the nutritional approach. Minneapolis, Minn: Winston Press, 1985.
Find full text
5
Beyond gluten intolerance: GIS, gluten inflammatory syndrome. Ashland, Ohio: BookMaster, Inc, 2012.
Find full text
6
Kellas, Bill. Toxic immune syndrome diet: Understanding of nutritional immune support. [United States]: B. Kellas, 1990.
Find full text
7
1953-, Stewart Alan, Abraham Guy, and Women's Nutritional Advisory Service, eds. Beat PMS through diet: The medically proven Women's Nutritional Advisory Service programme. London: Vermilion, 1994.
Find full text
9
Irritable bowel syndrome: Recipes & advice to control symptoms. London: Hamlyn, 2004.
Find full text
10
Westcott, Patsy. Irritable bowel syndrome: Recipes and advice to control symptoms. London: Hamlyn, 2002.
Find full textBook chapters on the topic "Wasting Syndrome, diet therapy"
1
Allison, Kelly C., and David B. Sarwer. "Diet, Exercise, and Behavior Therapy in the Treatment of Obesity and Metabolic Syndrome." In Metabolic Syndrome, 783–95. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-11251-0_43.
Full text
2
Allison, Kelly C., and David B. Sarwer. "Diet, Exercise, and Behavior Therapy in the Treatment of Obesity and Metabolic Syndrome." In Metabolic Syndrome, 1–14. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-12125-3_43-1.
Full text
3
Timpone, Joseph G., David J. Wright, Ning Li, Merrill J. Egorin, Mary E. Enama, Jacqueline Mayers, Giorgio Galetto, et al. "The Safety and Pharmacokinetics of Single-Agent and Combination Therapy with Megestrol Acetate and Dronabinol for the Treatment of HIV Wasting Syndrome." In Marihuana and Medicine, 701–16. Totowa, NJ: Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-710-9_69.
Full text
4
Dâmaso, Ana, Lian Tock, Aline de Piano, and Rajaventhan Srirajaskanthan. "Nutritional And Clinical Strategies On Prevention And Treatment Of Nafld And Metabolic Syndrome." In Nutrition, Diet Therapy, and the Liver, 113–30. CRC Press, 2009. http://dx.doi.org/10.1201/9781420085501.ch8.
Full text
5
Turan, Belma, and Erkan Tuncay. "High Carbohydrate Diet-Induced Metabolic Syndrome in the Overweight Body." In Personalized Nutrition as Medical Therapy for High-Risk Diseases, 153–82. CRC Press, 2020. http://dx.doi.org/10.1201/9781315112374-6.
Full text
6
Nishikawa, Yasuhiro. "Effects and Issues of Diet Fat on Cardiovascular Metabolism." In New Insights Into Metabolic Syndrome [Working Title]. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.93261.
Full textAbstract:
Diet is a foundation of treatment for lifestyle-related diseases, such as high blood pressure, diabetes, and dyslipidemia. For these diseases, diet therapy has been disregarded in management of hyperlipidemia. Fat has more diversity of biological effects compared to those of protein and carbohydrate. New emerging evidences have resulted in a clear shift of recognition of fatty acids in diet therapy. The PREDIMED study has shown recently the amazing result that a calorie-unlimited, high-fat Mediterranean diet caused about 30% reduction in cardiovascular disease in obese subjects compared with a low-fat diet. Many authorities have removed restriction of intake of fat from their guidelines. The important, new message from recent medical and nutritional science is that people need to consume more “good fat” rather than limiting intake of fat to prevent cardiometabolic diseases. In this chapter, I would like to focus on the role of fatty acids with special relation on their effects on blood lipids and cardiovascular events.
7
Bergin, Ann M. "Ketogenic Diet in Established Epilepsy Indications." In Ketogenic Diet and Metabolic Therapies, edited by Susan A. Masino, Detlev Boison, Dominic P. D’Agostino, Eric H. Kossoff, and Jong M. Rho, 50–62. Oxford University Press, 2022. http://dx.doi.org/10.1093/med/9780197501207.003.0007.
Full textAbstract:
The ketogenic diet (KD) provides an alternative strategy for seizure control in medication-resistant epilepsy. It is particularly valuable for those medication-resistant patients who are not surgical candidates. Years of observational evidence have been recently supported by a randomized controlled study indicating the benefit of diet treatment in children with refractory epilepsy, compared with a control group who delayed diet treatment for 3 months. Well-established uses include children with refractory, nonsurgical epilepsies, as well as epileptic encephalopathies, including infantile spasms and West syndrome, Lennox-Gastaut syndrome, and Dravet and Doose syndromes. The efficacy and role of diet therapy in these conditions are discussed.
8
Poff, Angela M., Shannon L. Kesl, Andrew P. Koutnik, Sara E. Moss, Christopher Q. Rogers, and Dominic P. D’Agostino. "Ketone Supplementation for Health and Disease." In Ketogenic Diet and Metabolic Therapies, edited by Susan A. Masino, Detlev Boison, Dominic P. D’Agostino, Eric H. Kossoff, and Jong M. Rho, 392–422. Oxford University Press, 2022. http://dx.doi.org/10.1093/med/9780197501207.003.0033.
Full textAbstract:
The physiologic state of ketosis is characterized by decreased blood glucose, suppression of insulin, and an increase in the blood ketones β-hydroxybutyrate (βHB) and acetoacetate (AcAc), which serve as alternative sources of ATP in the brain. Ketones are elevated by fasting, caloric restriction, exercise, or the ketogenic diet (KD), and until recently these were the only known methods of inducing and sustaining ketosis in a nonpathologic setting. Many studies have revealed therapeutic effects of the KD, and data suggest that the benefits are mediated largely by ketone body metabolism and signaling. However, the KD often causes reduced patient compliance, which can make the KD a suboptimal long-term treatment. This has led researchers to develop exogenous ketone supplements—compounds that release or are metabolized into βHB and/or AcAc. The supplements rapidly elevate blood ketones in a dose-dependent manner, making them a practical method for inducing therapeutic ketosis. Ketone supplementation could potentially be used as stand-alone therapy in certain conditions, or possibly as a way to further augment the efficacy of the KD in the conditions in which it is being used or investigated, and it could increase compliance by allowing patients to maintain a less restrictive diet. Ketone supplements may also serve as an effective preventative medicine due to their potential to protect and enhance mitochondrial function. Preliminary evidence suggests there are several conditions for which ketone supplementation may be beneficial, including epilepsy, Alzheimer’s disease, glucose transporter type 1 deficiency syndrome, cancer, atrophy-related diseases, and metabolic syndrome.
9
Hsiang-Yi Chou, Sherry. "Subarachnoid Hemorrhage." In Neurocritical Care, edited by Namir Khandker and Lori A. Shutter, 44–53. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199375349.003.0006.
Full textAbstract:
Subarachnoid hemorrhage (SAH) affects over 30,000 Americans per year, leaves over half of its survivors in severe disability, and has a mortality rate of approximately 20%. SAH syndrome presents with a complex disease course and symptoms involving both the central nervous system (CNS) as well as extra-CNS systems. SAH may lead to early brain injury, cerebral vasospasm, and delayed cerebral ischemia, which increases SAH morbidity and mortality. SAH-related extra-CNS organ injuries include neurogenic stunned myocardium, neurogenic pulmonary edema, syndrome of inappropriate antidiuretic hormone secretion, cerebral salt wasting syndrome, systemic inflammatory response syndrome, fever, and venous thromboembolism, all of which require careful critical care management. Though multiple randomized trials in the recent years have not successfully identified any effective neuroprotective therapy in SAH, the overall SAH outcome has significantly improved over the past two decades.
10
Li, Jie Jack. "Diabetes Drugs." In Laughing Gas, Viagra, and Lipitor. Oxford University Press, 2006. http://dx.doi.org/10.1093/oso/9780195300994.003.0011.
Full textAbstract:
Diabetes mellitus is a multisystem disease associated with the loss of control of physiological glucose concentrations in the blood. The disease is broadly broken down into two types based on factors that include age, acuteness of onset, underlying glucose-handling deficit, and therapy. Type 1 diabetes usually manifests acutely in the young, secondary to some underlying insult (possibly infectious) to the islet cells of the pancreas, resulting in an absolute lack of insulin. Type 2 diabetes is more frequently associated with maturity, obesity, and gradually increasing blood glucose concentrations; it may be asymptomatic for some time and discovered on routine glucose screening. In fact, as weight increases among the general population of the developed world, type 2 diabetes is becoming an epidemic. Type 1 diabetes always requires insulin replacement therapy, whereas type 2 can frequently be controlled with diet, weight loss, and oral medications that enhance residual pancreatic function. Diabetes has been known since antiquity. In fact, the term diabetes mellitus comes from the Greek meaning “siphon and honey” due to the excess excretion (siphon or faucet) of hyperglycemic (sweetened, or honeyed) urine. In ancient times, most cases of diabetes were of type 1, with acute onset in the young, which was often fatal. Type 2 diabetes was extremely rare when sources of nutrition were scarce and obesity was not prevalent. Diabetes was also known as “wasting” because diabetics were not able to metabolize the sugar content of food and eventually died from wasting away. Because of the effect of excess blood glucose, the blood of the diabetic is hyperosmolar (concentrated), and this triggers compensatory thirst (in an attempt to dilute the hyperglycemia and return the blood to a normal concentration). This excess thirst results in the common diabetic symptom of polydipsia (excessive drinking secondary to thirst, resulting in the urge to drink frequently) and polyuria (excess urination). Even before many modern diagnosis tools became available, savvy doctors could diagnose diabetic men just by looking at their shoes for the telltale white spots from urine with high sugar content. In fact, tasting urine samples of diabetics was a routine diagnostic tool for diabetes. Even the breath of a severe diabetic was sweet—a sickly smell as a result of acidosis. In addition, it has been mentioned that ants would track to the urine of diabetics.
Conference papers on the topic "Wasting Syndrome, diet therapy"
1
Luo, Yansong, Chunrong Liu, and Kong Fan Qiang. "Extraction of Key Factors to Determining the Acceptability of Diet Therapy Based on Syndrome Differentiation of Traditional Chinese Medicine." In 13th International Conference on Applied Human Factors and Ergonomics (AHFE 2022). AHFE International, 2022. http://dx.doi.org/10.54941/ahfe1002033.
Full textAbstract:
Purpose: Extract key factors to determining the acceptability of diet therapy based on syndrome differentiation of Traditional Chinese Medicine for middle-aged and elderly people and propose some suggestions to improve their acceptance of it. Method: Thirteen main influencing factors are selected from literature survey and interviews. Semi-structured interview are conducted with Decision-Making Trial and Evaluation Laboratory questionnaires to evaluate factors’ interrelationship. Results: The understandability and the memorability of medicinal food’s knowledge, the type of medicinal food and the popularity of medicinal food’s knowledge are key influencing factors. Suggestions: Pre-research of people’s taste preferences is important and necessary; the identity of propagandist and the source of propaganda content should be transparent and the organization of publicity activities should be normalized; concise and multi-sensory propagation mode should be adopted; “Medicinal Virtue Association” can be used to reduce the difficulty of memorizing knowledge.
2
Rodrigues, Bruno Cassis Antunes, Francisco Tomaz Meneses de Oliveira, and Rubens José Gagliardi. "Importance of early diagnosis of galactosemia and encephalopathy: case report." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.483.
Full textAbstract:
Introduction: Galactosemia is an autosomal recessive genetic condition, with alteration of galactose metabolism, leading to increased serum concentration of galactose (galactosemia). The first symptoms occur in the neonatal period, associated with the ingestion of galactose. Untreated patients usually have growth failure, liver and kidney dysfunction, tubulopathies, encephalopathy and susceptibility to infections. Case report: We describe a case of diagnostic investigation of a patient born at 38 weeks, after an uncomplicated gestation, with congenital cataracts, hepatomegaly, diabetes and Fanconi syndrome, as well as encephalopathy, hypotonia and cognitive deficit. She remained in the service for 15 days for diagnostic investigation, leading to hypothesis of galactosemia, confirmed later with genetic testing. Until then, the patient received unrestricted food, being instructed to change the diet, eliminating foods with galactose. After diagnosis, guidance and appropriate treatment were possible. Currently, patient is 20 years old, being monitored by neurology, ophthalmology, hepatology, occupational therapy and speech therapy teams. Conclusions: Brazil does not have neonatal screening for galactosmia, thus, the clinical recognition of its initial signs is important for early diagnosis and treatment, avoiding further complications and sequelae.
3
Moreira, Lorrane de Moura, Bruna Stefany Alves Françozo, Bruno Barcelos Pereira, Camila Almeida Sardinha, Débora Pimenta Alves, Filipe Henrique Almeida Barbosa Godoi, Katherine Oliveira Ferreira, and Silvia Oliveira Dourado. "Diagnosis and treatment of Multiple sclerosis: Brazilian and global overview." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.490.
Full textAbstract:
Introduction: Multiple sclerosis (MS) is a neurodegenerative autoimmune disease of the central nervous system with a chronic, progressive and inflammatory character. In addition, it presents itself in a heterogeneous way, and can be as an isolated syndrome or as a recurrent remitter, in the first stage, or as progressive, in the second stage. The present work was developed with the objective of determining which is the best form of diagnosis and therapy for multiple sclerosis in Brazil. Methods: The review was performed in PubMed platform, with the descriptors: “multiple sclerosis”, “diagnosis”, “therapy” and “research”. Results: The research result in 148 articles. After a criterious reading and the application of the used criteria, was selected 20 articles. Conclusion: For the diagnosis of this chronic neurological disease, magnetic resonance imaging is used to assess myelination of the different regions of the central nervous system, which is the most suitable for the diagnosis of MS. Μoreover, as a complement, cerebrospinal fluid extraction and blood tests are performed in order to ascertain the concentration of B cells. Regarding therapeutics, this is diversified, including drugs, diets and therapies that stimulate cognition and motor action, such as the use of virtual reality programs and motor images. In relation to drugs, it is of importance that SUS makes natalizumab and ocrelizumab available because they are more efficient and enable users to have a better quality of life. Finally, nutritional monitoring is also suggested to establish a ketogenic or fasting diet in a balanced way
Reports on the topic "Wasting Syndrome, diet therapy"
1
Chen, Shu-xian, Mei-ying Ao, Xing-qian Yi, Qing-ying He, Qian Chen, Rui-rong Zhang, Jia-wei Dong, Jia-hui Zhang, and Xiao-fan Chen. Effectiveness of Traditional Chinese medicine syndrome differentiation diet therapy in intervention of type 2 diabetes: protocol for a systematic review and meta-analysis of randomised controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2021. http://dx.doi.org/10.37766/inplasy2021.6.0097.
Full text